Tag: ILLUMENATE
ILLUMENATE four-year pooled analysis has “brought increased clarity” to the paclitaxel...
Sean Lyden (Cleveland, USA), current VIVA Board president, speaks to Vascular News about his two years at the helm, which began with the “controversy on...
Four-year results from patient-level meta-analysis confirm safety profile of Philips Stellarex...
Royal Philips today announced the results of a patient-level meta-analysis that confirms the safety profile of its Stellarex drug-coated balloon (DCB) at four years....
Endovascular late-breaking trials presented at TCT 2020
Findings from a series of late-breaking trials in the endovascular field were presented recently at TCT Connect (14–18 October, virtual), the 32nd annual scientific...
Late-breaking ILLUMENATE data demonstrate three-year safety and efficacy for Stellarex DCB
Three-year results from the ILLUMENATE Pivotal trial and the ILLUMENATE European randomised controlled trial (EU RCT) have been presented in a late-breaking trial session...
Positive results for Spectranetics Stellarex demonstrated in ILLUMENATE 12-month data
The final 12-month results of the Stellarex (Spectranetics) drug-coated balloon ILLUMENATE Global Study have found high primary patency and freedom from clinically driven target...
